NuCana (NCNA) said Monday that initial data from an ongoing Phase 1b/2 study of NUC-3373 in combination with pembrolizumab indicated a significant reduction in tumor volume in patients with lung cancer.
"NUC-3373 may be an attractive alternative to pemetrexed in patients with NSCLC and mesothelioma," David Harrison, NuCana's head of translational medicine, said in a release. "Observing that NUC-3373 in combination with docetaxel is stabilizing disease in these hard-to-treat patient populations provides further evidence supporting this hypothesis."
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。